Hópital Pitié Salpétriere, Paris — France
The development of fotemustine in its various indications, on more than 1 800 treated patients, and in studies conducted throughout Europe since 1985, is presented below:
Indication Fotemustine alone (pts) Combination (pts)
Melanoma 312 485
Glioma 129 195
Lung (NSC) 172 77
Kidney 84 20
Colon 36 44
LA. Route 125
These data confirm:
— the activity of fotemustine in disseminated malignant melanoma, either as monochemotherapy (16.4—47 % response rate (RR)) or in combination with dacarbazine or vindesine.
— the interest of the drug in gliomas: either recurrent (RR = 26.3 %) or inoperable (RR = 29 % when combined with radiotherapy)
— the benefit in NSC lung cancer with a RR close to 20 % in relapses of conventional first line chemotherapy.
Studies are ongoing in various indications (kidney, colon, IA route, cervix, ovary) and available results will be presented.
Current development of the nitrosourea fotemustine: results and perspectives
